VXX-301 / Vaxxinity - LARVOL DELTA

Drug Development. (PubMed, Alzheimers Dement) - "Here we present preclinical data indicating that VXX-301 is immunogenic and induces antibodies with favorable characteristics. VXX-301 antibodies exhibit binding to specific targeted regions as well as multiple forms of full-length Tau. Moreover, we show that VXX-301 antibodies bind to Tau in human brain tissue samples. VXX-301 demonstrates both in vitro and in vivo efficacy against Tau-dependent phenotypes, supporting the further development of this vaccine as a treatment and prevention of AD and other tauopathies."

Journal • Alzheimer's Disease • Ataxia • CNS Disorders • Movement Disorders

VXX-301, a muti-epitope active immunotherapy targeting Tau, induces antibodies with favorable binding to Tau and exhibits efficacy in vivo (AAIC 2024) - "Here we present preclinical data indicating that VXX-301 is immunogenic and induces antibodies with favorable characteristics. VXX-301 antibodies exhibit binding to specific targeted regions as well as multiple forms of full-length Tau. Moreover, we show that VXX-301 antibodies bind to Tau in human brain tissue samples."

Preclinical • Alzheimer's Disease • Ataxia • CNS Disorders • Movement Disorders